Eli Lilly shares rose after the company reported second-quarter results that beat analyst expectations, driven by continued revenue momentum from tirzepatide marketed as Zepbound for obesity and Mounjaro for adult type 2 diabetes. The StockWatch report says Lilly also raised its 2026 GAAP revenue guidance. The recap attributes the investor reaction to operating leverage and income statement outperformance, noting that guidance was supported by acquisition-related in-process research and development charges tied to the Orna Therapeutics and Ajax Therapeutics deals. For biotech investors, the update reinforces that GLP-1/GIP franchise cash flows remain the sector’s key backstop for pipeline investment, while raising questions about how future growth will depend on expanded indications and cost discipline.